# Lutein Supplementation Eye Health Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/lutein-supplementation-eye-health-randomized-trial-evidence-review
Category: evidence-review
Summary: Lutein Supplementation Eye Health Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this fir
Last reviewed: 2026-06-28
Reviewed by: Migaku Evidence Review
# Lutein Supplementation Eye Health Randomized Trial: What the Evidence Says

## Quick Answer

Lutein Supplementation Eye Health Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 randomized trial, 1 research article.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Effect of carotenoids supplementation on visual function in Chinese adults free of retinal disease: protocol for the CSV double-blind, randomised, placebo-controlled trial | randomized trial | 2 | 2026-01-01 | 10.1136/bmjopen-2025-112364 |
| Nutritional supplements: current evidence for retinitis pigmentosa and Stargardt disease | research article | 4 | 2026-05-01 | 10.1097/ICU.0000000000001213 |

## What The Sources Report

- It aims to provide high-quality evidence on the impact of dietary carotenoid supplementation on visual function in the normal Chinese population, supporting nutritionists and physicians in improving visual function through dietary interventions and paving the way for future large-scale clinical studies. [Xu Kan (2026); evidence level 2]
- These carotenoids are specifically concentrated in the macula lutea via high-affinity binding proteins and specialised transport and metabolic proteins.However, humans are unable to synthesise carotenoids such as L and Z. [Xu Kan (2026); evidence level 2]
- The standard of care for many IRDs has largely focused on managing associated complications and the use of optical aids to improve quality of life. [Barthelemy Normila (2026); evidence level 4]
- This review synthesizes both historical and contemporary evidence regarding dietary and nutritional interventions for IRDs.  14 Retinitis pigmentosa is one of the most common IRDs and is characterized by progressive photoreceptor cell death. [Barthelemy Normila (2026); evidence level 4]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For lutein supplementation eye health randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Xu Kan (2026). Effect of carotenoids supplementation on visual function in Chinese adults free of retinal disease: protocol for the CSV double-blind, randomised, placebo-controlled trial. DOI: 10.1136/bmjopen-2025-112364. PMCID: PMC13034290. PMID: 41887628. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13034290/
- Barthelemy Normila (2026). Nutritional supplements: current evidence for retinitis pigmentosa and Stargardt disease. DOI: 10.1097/ICU.0000000000001213. PMCID: PMC13034758. PMID: 41861379. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open a.... https://pmc.ncbi.nlm.nih.gov/articles/PMC13034758/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.